Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
Pods of Potential
Iowa Soybean Association & Iowa Agribusiness Radio Network
The Madness of Chartrulean
Packhowl Media
AASR Live
The Alliance Against Seclusion and Restraint
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Lloyd Burrell, Keith Block M.D., Jeffrey Smith, Michael Klaper M.D., Ralph Moss, Brenda Davis R.D., Mark Sloan, Gerald Posner, Ian Harris M.D., Neil Barnard M.D., Will Tuttle Ph.D., John McDougall M.D., Pam Popper Ph.D., Gabriel Cousens M.D., Brian Clement Ph.D., Anna Maria Clement Ph.D., Marianne Williamson, Vandana Shiva Ph.D., Aly Cohen M.D., Milton Mills M.D., Theodora Scarato, William Li M.D., David Katz M.D., Stephanie Seneff Ph.D., Julieanna Hever M.S., Dale Bredesen M.D., Hope Bohanec, Kim Williams M.D., Joel Kahn M.D., Michelle Perro M.D., David Wolfe, Melanie Joy Ph.D., Sunil Pai M.D., Baxter Montgomery M.D., Michael Greger M.D., Caldwell Esselstyn M.D., Joel Fuhrman M.D., Colin Campbell Ph.D.
GL DEEP DIVES
Gorgorod
Dark Mysteries — Unsolved Mysteries. Forgotten Secrets. Unanswered Questions.
Darkest Mysteries Online
Thrilling Threads - Conspiracy Theories, Strange Phenomena, True Crime, Unsolved Mysteries, etc!
Byte & Pieces
Sahil Adeem Podcast
Sahil Adeem
La Ruta Secreta
Emisor Podcasting
Nightmare Creature (Creepy Military Stories)
Nightmare Creature
Beyond the Void: Philosophy & Psychology for the Modern Mind
btv
The Interventional Endoscopist
Mankanwal Sachdev
Pillole di Scienza
Massimo Dell'Erba
Fox Weather Update
Fox Weather
San Antonio Weather Daily
Fast Foundations
Houston Weather Daily
Fast Foundations
Migraine Relief Code with Dr. Amelia Scott Barrett, MD
Dr. Amelia Scott Barrett, MD
Einschlafen mit Psychologie
Hendler Dynasty Media
The Many Shades of Green
Hudson River Radio .com
Bee Love Beekeeping... presented by Mann Lake
Eric Bennett
The Spoon Podcast
The Spoon
What in the world is dyscalculia?
Dr. Honora Wall, Ed.D.
PBS News Hour - Science
PBS News
New Books in Communications
Marshall Poe
Scholarly Communication
New Books Network
The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
CME in Minutes: Education in Dermatology
Answers in CME
The BioCentury Show
BioCentury
The European Molecular Biology Laboratory (EMBL) Alumni Chats Series
EMBL Alumni Relations
Permaculture P.I.M.P.cast
Permaculture P.I.M.P.cast
Resoundingly Human
INFORMS
Harrison's PodClass: Internal Medicine Cases and Board Prep
AccessMedicine
Aha! Zehn Minuten Alltags-Wissen
WELT
Dear Psychopomp: Let's Talk About Death
Anne-Marie // BC, Canada
Typical Skeptic Podcast
Robert Kalil
Ciencia
BioCentury
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank...
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in S...
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The...
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing th...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCen...
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, accordi...
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-fou...
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting s...
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI...
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower re...
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypoth...
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move id...
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to con...
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary s...
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by techno...
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.If you c...
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic ca...
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though...
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of bio...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.